Skip to main content

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Recruiting · Phase 3 · NCT06119581

Conditions: Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

At a glance

Research payments reported, 2025
$7.4M
U.S. investigators named
82
Sites paid
93
Planned or actual enrollment
1,264

About the trial

Sponsor
Eli Lilly and Company
Tested
LY3537982 (drug), Pembrolizumab (drug), Placebo (drug), Cisplatin (drug), Carboplatin (drug), Pemetrexed (drug)
Dates
Started 2023-12-21; completion 2031-01
Results posted
Not yet

The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change in a gene called KRAS G12C. Study participation, including follow-up, could last up to 3 years, depending on how you and your lung cancer are doing.

From ClinicalTrials.gov, last updated 2026-11-04. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Eli Lilly and Company reported $7.4M in research payments for this study in 2025 (156 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.